Brought to you by 
Tilex gets global rights to Wilex's imaging agent Redectane
03 Feb 2017
Executive Summary
Wilex AG granted newly launched Telix Pharmaceuticals Ltd. exclusive global rights to develop, manufacture, and sell Redectane, an iodine-labelled form of the chimeric monoclonal antibody girentuximab that is in Phase III as an imaging agent for clear cell renal cell carcinoma (ccRCC).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tilex gets global rights to Wilex's imaging agent Redectane
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice